Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Anesthesiology ; 139(4): 511-522, 2023 10 01.
Artigo em Inglês | MEDLINE | ID: mdl-37698434

RESUMO

The traditional paradigm of oncologic treatment centered on cytotoxic chemotherapy has undergone tremendous advancement during the last 15 yr with the advent of immunotherapy and targeted cancer therapies. These agents, including small molecule inhibitors, monoclonal antibodies, and immune-checkpoint inhibitors, are highly specific to individual tumor characteristics and can prevent cell growth and tumorigenesis by inhibiting specific molecular targets or single oncogenes. While generally better tolerated than traditional chemotherapy, these therapies are associated with unique constellations of adverse effects. Of particular importance in the perioperative and periprocedural settings are hematologic abnormalities, particularly antiplatelet effects with increased risk of bleeding, and implications for wound healing. This narrative review discusses targeted cancer therapies and provides recommendations for physicians managing these patients' care as it relates to procedural or surgical interventions.


Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Neoplasias , Humanos , Imunoterapia , Período Perioperatório , Proliferação de Células , Cicatrização , Neoplasias/tratamento farmacológico
3.
Am J Health Syst Pharm ; 81(4): 112-119, 2024 Feb 08.
Artigo em Inglês | MEDLINE | ID: mdl-37675967

RESUMO

PURPOSE: Ibrutinib is a Bruton's tyrosine kinase inhibitor used to treat multiple hematologic malignancies and graft-versus-host disease. Though less myelosuppressive than cytotoxic chemotherapy, increased infections, including invasive fungal infections (IFIs), have been reported with ibrutinib use. This study aimed to determine the characteristics and risk factors for infection associated with ibrutinib at our institution. METHODS: Patients who received ibrutinib between June 2014 and August 2019 were included. Primary endpoints were the incidence of any infection and the incidence of serious infection (defined as hospitalization, parenteral antimicrobial therapy, or pneumonia regardless of hospitalization). Infection risk factors were assessed using logistic regression. RESULTS: One hundred thirty-two patients were identified (78% male; median age, 71 years). The most common indications for ibrutinib were chronic lymphocytic leukemia (67%) and mantle cell lymphoma (12%). Infection and serious infection occurred in 94 (71%) and 47 (36%) patients, respectively; when pneumonia was excluded as a criterion for serious infection, the serious infection rate was 27%. The median time from ibrutinib initiation to first infection was 125 days. Prior allogeneic hematopoietic stem cell transplantation (allo-HSCT) (odds ratio [OR], 4.60; 95% CI, 1.22-17.4) and corticosteroid use (OR, 5.55; 95% CI, 1.52-20.3) were significant risk factors for serious infection. IFIs were diagnosed in 7 patients (5%): 5 had Pneumocystis jirovecii pneumonia and 2 were infected with invasive molds. CONCLUSION: Serious infection and IFI rates are high but similar to those previously described. Risk factors for serious infection included allo-HSCT and corticosteroid use. Targeted antimicrobial prophylaxis should be evaluated in prospective studies in patients on ibrutinib to reduce serious infections and IFI.


Assuntos
Adenina/análogos & derivados , Anti-Infecciosos , Neoplasias Hematológicas , Leucemia Linfocítica Crônica de Células B , Piperidinas , Pneumonia , Humanos , Adulto , Masculino , Idoso , Feminino , Estudos Prospectivos , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Leucemia Linfocítica Crônica de Células B/patologia , Neoplasias Hematológicas/tratamento farmacológico , Neoplasias Hematológicas/epidemiologia , Anti-Infecciosos/uso terapêutico , Corticosteroides/uso terapêutico
4.
Anticancer Res ; 33(10): 4163-74, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24122979

RESUMO

Prostate cancer continues to be one of the most commonly diagnosed diseases and the second leading cause of cancer-related deaths among men in the United States. Options exist to treat localized disease, including surgery, radiation therapy, and hormonal therapy, but clinical management of advanced prostate cancer is challenging. In the past few decades, chemoprevention involving naturally-occurring compounds has emerged as a promising and cost-effective approach to reduce incidence and morbidity of prostate cancer by inhibiting the precancerous events before the occurrence of clinical disease. The present review focuses on summarizing the recent advances in studies of major dietary phytochemicals and their role in prostate cancer development.


Assuntos
Anticarcinógenos/farmacologia , Compostos Fitoquímicos/farmacologia , Neoplasias da Próstata/prevenção & controle , Animais , Capsaicina/farmacologia , Carotenoides/farmacologia , Quimioprevenção , Curcumina/farmacologia , Humanos , Licopeno , Masculino , Resveratrol , Estilbenos/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA